Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: Findings from the Icatibant Outcome Survey
Allergy, Asthma & Clinical Immunology Aug 11, 2017
Aberer W, et al. – This study aimed to assess the characteristics of breakthrough attacks and the effectiveness of icatibant as a treatment option using the Icatibant Outcome Survey (IOS). In this study, experts encouraged patients who use long–term prophylaxis (LTP) to be aware of severity and existence of breakthrough attacks. It was reported that icatibant was effective for the treatment of breakthrough attacks.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
